S. Maheswaran

Response-guided neoadjuvant sacituzumab govitecan for localized triple negative breast cancer: results from the NeoSTAR trial.

L. Trippa, L. Ellisen, A. Comander, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.